Caribou Biosciences (CRBU) Non-Current Deffered Revenue (2020 - 2026)

Caribou Biosciences (CRBU) has reported Non-Current Deffered Revenue for 7 consecutive years, with $1.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Non-Current Deffered Revenue fell 37.12% year-over-year to $1.6 million; the TTM figure through Mar 2026 stood at $1.6 million (down 37.12% YoY), while the FY2025 annual figure was $1.8 million, down 47.18% from the prior year.
• Non-Current Deffered Revenue retreated to $1.6 million in Q1 2026 per CRBU's latest filing, from $1.8 million in the prior quarter.
• Across five years, Non-Current Deffered Revenue topped out at $18.2 million in Q2 2023 and bottomed at $1.6 million in Q1 2026.
• Historically, Non-Current Deffered Revenue has averaged $6.9 million across 5 years, with a median of $4.6 million in 2024.
• Annual changes were most pronounced in 2022 — Non-Current Deffered Revenue jumped 741.41% — and 2024, when it slumped 74.65%.
• Caribou Biosciences' Non-Current Deffered Revenue stood at $16.0 million in 2022, then slumped by 61.75% to $6.1 million in 2023, then slumped by 45.64% to $3.3 million in 2024, then plunged by 47.18% to $1.8 million in 2025, then declined by 5.94% to $1.6 million in 2026.
• Business Quant data shows CRBU's Non-Current Deffered Revenue at $1.6 million in Q1 2026, $1.8 million in Q4 2025, and $1.8 million in Q3 2025.